U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Surveillance: Post Drug-Approval Activities
  5. FDA's Adverse Event Reporting System (FAERS)
  6. Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between April - June 2014
  1. FDA's Adverse Event Reporting System (FAERS)

Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between April - June 2014


Product Name: Active Ingredient (Trade) or Product Class		 Potential Signal of a Serious Risk / New Safety Information Additional Information
(as of January 27, 2020)
Everolimus (Zortress) Pulmonary hypertension; Pulmonary arterial hypertension

The Warnings and Precautions section of the everolimus labeling was updated November 2015 to include information about pulmonary hypertension and pulmonary arterial hypertension.


Zortress label
Back to Top